PMID- 22310339
OWN - NLM
STAT- MEDLINE
DCOM- 20120612
LR  - 20181201
IS  - 1423-0240 (Electronic)
IS  - 0378-584X (Linking)
VI  - 35
IP  - 1-2
DP  - 2012
TI  - Administration of 24-h intravenous infusions of trabectedin in ambulatory 
      patients with mesenchymal tumors via disposable elastomeric pumps: an effective 
      and patient-friendly palliative treatment option.
PG  - 14-7
LID - 10.1159/000335879 [doi]
AB  - BACKGROUND: Patients with progressive mesenchymal tumours after standard 
      chemotherapy have poor outcome. Trabectedin is approved in Europe as 24-h 
      intravenous (i.v.) infusion q3w in this setting. We report the use of disposable 
      elastomeric pumps for ambulatory treatment with trabectedin. MATERIAL AND 
      METHODS: Pre-treated sarcoma patients were offered trabectedin 1.5 mg/m(2) as 
      24-h i.v. infusion via port catheter, either as inpatients using electronic pumps 
      or as outpatients using the Baxter LV10 pump. Co-medication consisted of 
      antiemetics including dexamethasone. RESULTS: 21/28 patients with distant 
      metastasis and/or local relapse elected outpatient therapy and received 130 
      cycles (median 3, range 1-24). Dose reductions were done in 60 cycles, mainly due 
      to laboratory adverse events (AEs). Best response (Response Evaluation Criteria 
      in Solid Tumours (RECIST)) was 4 cases of confirmed partial remission (PR), 6 
      cases of stable disease (SD), and 11 cases of progressive disease (PD). Grade 3/4 
      (Common Toxicity Criteria (CTC)) AEs were limited to 1 case each of haemorrhage 
      and lung embolism; other AEs were in line with published trabectedin experience. 
      1 port catheter contamination required replacement, 1 catheter thrombosis 
      occurred and 1 extravasation due to needle dislocation was observed. CONCLUSIONS: 
      Outpatient administration of trabectedin as 24-h infusion using Baxter LV10 pumps 
      is preferred by the vast majority of patients; it is feasible, safe, effective, 
      cost efficient, and should be considered as routine practice in this clinical 
      setting.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Schoffski, Patrick
AU  - Schoffski P
AD  - Department of General Medical Oncology, Leuven Cancer Institute, University 
      Hospitals Leuven, Belgium. patrick.schoffski@uzleuven.be
FAU - Cerbone, Linda
AU  - Cerbone L
FAU - Wolter, Pascal
AU  - Wolter P
FAU - De Wever, Ivo
AU  - De Wever I
FAU - Samson, Ignace
AU  - Samson I
FAU - Dumez, Herlinde
AU  - Dumez H
FAU - Clement, Paul
AU  - Clement P
FAU - Wildiers, Hans
AU  - Wildiers H
FAU - Stas, Marguerite
AU  - Stas M
LA  - eng
PT  - Journal Article
DEP - 20120120
PL  - Switzerland
TA  - Onkologie
JT  - Onkologie
JID - 7808556
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Dioxoles)
RN  - 0 (Tetrahydroisoquinolines)
RN  - ID0YZQ2TCP (Trabectedin)
SB  - IM
MH  - Ambulatory Care/*methods
MH  - Antineoplastic Agents, Alkylating/administration & dosage
MH  - Dioxoles/*administration & dosage
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - *Infusion Pumps, Implantable
MH  - Infusions, Intravenous/instrumentation/methods
MH  - Male
MH  - Middle Aged
MH  - Palliative Care/*methods
MH  - Patient Satisfaction
MH  - Sarcoma/*drug therapy/*pathology
MH  - Tetrahydroisoquinolines/*administration & dosage
MH  - Trabectedin
MH  - Treatment Outcome
EDAT- 2012/02/09 06:00
MHDA- 2012/06/13 06:00
CRDT- 2012/02/08 06:00
PHST- 2012/02/08 06:00 [entrez]
PHST- 2012/02/09 06:00 [pubmed]
PHST- 2012/06/13 06:00 [medline]
AID - 000335879 [pii]
AID - 10.1159/000335879 [doi]
PST - ppublish
SO  - Onkologie. 2012;35(1-2):14-7. doi: 10.1159/000335879. Epub 2012 Jan 20.